The tweet was deleted by the author.
But we saved everything 🙂.
Eyepoint Pharmaceuticals is advancing potential therapies targeting serious retinal diseases such as diabetic macular edema (DME) as part of its observance of Mens Health Month in June.
The company emphasizes its commitment to improving patient outcomes through ongoing research and development in ophthalmology. Eyepoint Pharmaceuticals encourages patients and healthcare professionals to learn more about its latest efforts to address significant unmet medical needs in retinal care.
Eyepoint operates a research facility in Northbridge focused on developing new therapies for retinal disease patients, according to a previous company update. The company’s Chief Executive, Jay S. Duker, has also discussed advances in OCT retina imaging tools that have impacted retina care in recent years, as reported in a separate interview. These activities reflect Eyepoint’s ongoing involvement in ophthalmology innovation.